You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Colorectal cancer, Dalpiciclib, Efficacy and safety

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced/Metastatic Colorectal Cancer Trial in Guangzhou (Dalpiciclib, Oxaliplatin injection, Calcium folinate)

Not yet recruiting
  • Advanced/Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    Sixth Affiliated Hospital, Sun Yat-sen University
Jul 28, 2022

Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

Recruiting
  • Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Breast Cancer Trial in Shijiazhuang (Dalpiciclib, Aromatase inhibitor, Docetaxel injection)

Recruiting
  • Breast Cancer
  • Shijiazhuang, Hebei, China
    The Fourth Hospital of Hebei Medical University
Oct 25, 2023

Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Oct 10, 2022

Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 10, 2022

Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)

Recruiting
  • Sarcoma
  • Fluzoparib+ Dalpiciclib
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023

Breast Cancer Trial (dalpiciclib plus letrozole)

Not yet recruiting
  • Breast Cancer
  • dalpiciclib plus letrozole
  • (no location specified)
Aug 21, 2022

Breast Tumor Female Trial (Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy)

Not yet recruiting
  • Breast Neoplasm Female
  • Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
  • (no location specified)
Oct 17, 2022

Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Recruiting
  • Breast Cancer
  • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Mar 23, 2023

HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)

Not yet recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Oct 17, 2022

Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • Tianjin, China
    Tianjin Cancer Hospital
Mar 28, 2023

Advanced Breast Cancer Trial (Dalpiciclib+ letrozole +capecitabine)

Not yet recruiting
  • Advanced Breast Cancer
  • Dalpiciclib+ letrozole +capecitabine
  • (no location specified)
Jul 21, 2022

Luminal B/HER2-negative Breast Cancer Trial in Hangzhou (Dalpiciclib combined with aromatase inhibitors,

Recruiting
  • Luminal B/HER2-negative Breast Cancer
  • Dalpiciclib combined with aromatase inhibitors
  • anthracycline-cyclophosphamide followed by taxane
  • Hangzhou, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 30, 2022

Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

Recruiting
  • Advanced Breast Cancer
  • The combination of Dalpiciclib with physician-selected endocrine therapy
  • Chemotherapy selected by the physician
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 22, 2023

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Dec 2, 2022

Metastatic Breast Cancer Trial in Guangzhou, Shantou (Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole,

Not yet recruiting
  • Metastatic Breast Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Jul 17, 2022

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate

Not yet recruiting
  • High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
  • dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
  • placebo; abiraterone acetate tablets; prednisone tablets
  • (no location specified)
Oct 20, 2023

Breast Tumors Trial in Zhengzhou (Pyrotinib Maleate, Dalpiciclib Isethionate Tablets, Inetetamab)

Recruiting
  • Breast Neoplasms
  • Pyrotinib Maleate
  • +3 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 1, 2022

Solid Tumor Trial (Dalpiciclib)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 22, 2022

Advanced Breast Cancer Trial in Beijing (Dalpiciclib in combination with endocrine therapy by Physicians choice)

Not yet recruiting
  • Advanced Breast Cancer
  • Dalpiciclib in combination with endocrine therapy by Physicians choice
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Jun 19, 2022

Breast Cancer Trial in Shenyang (Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole)

Recruiting
  • Breast Cancer
  • Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Sep 12, 2022

Breast Cancer Trial in Shanghai (Letrozole, Pyrotinib, Dalpiciclib(SHR6390))

Recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 21, 2022

Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR

Not yet recruiting
  • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
  • +6 more
    • (no location specified)
    Aug 9, 2022